#None #Bio-Techne #Nucleai #SECOMBIT

Unveiling Predictive Biomarkers in Melanoma through Advanced AI Technology

In a significant scientific advancement, Bio-Techne Corporation and Nucleai have come together to present groundbreaking data at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. Their collaborative study utilizes advanced spatial biology techniques and AI-powered multimodal platforms to identify predictive biomarkers for melanoma patients undergoing immunotherapy and targeted therapy treatment.

Study Overview

The focus of this research is the SECOMBIT clinical trial, which aimed at understanding how immune cell interactions within tumor environments could inform treatment success. Under the leadership of Professor Paolo Ascierto from the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study examined 42 pre-treatment biopsies from patients with metastatic melanoma using Bio-Techne's COMET™ platform and a sophisticated 28-plex multiplex immunofluorescence (mIF) panel.

The innovative approach integrated high-plex imaging, histopathology, and clinical outcomes to reveal distinct immune cell interactions that correlate with vital patient metrics such as progression-free survival (PFS) and overall survival (OS).

Key Insights from the Study

• - Arm A (MAPKinhibitors followed by ICB): The presence of immune activation markers such as PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells was linked to improved patient outcomes, suggesting effective immune engagement.
• - Arm B (ICB followed by MAPKinhibitors): A correlation was observed between PD-1+ CD8 T-cells situated in the tumor invasive margin and interactions with PD-L1+ CD4 T-cells leading to better survival metrics.
• - Arm C (Combination of therapies): Notable interactions between antigen-presenting cells (APCs) and T-cells at tumor margins were associated with favorable outcomes. Conversely, macrophage interactions in the surrounding tumor microenvironment indicated a potentially poorer prognosis.

The research strongly indicates that not only does the location of immune cells within the tumor play a crucial role, but also the nature of their interactions. By leveraging AI and spatial biology techniques, the study aims to predict which patients might benefit the most from specific therapies, marking a step forward in personalized cancer treatment.

Transformational Impact

Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, stated, "This study exemplifies how our innovative spatial imaging and analysis workflow can be broadly applied to clinical research, transforming clinical decision-making in immuno-oncology."

Likewise, Avi Veidman, CEO of Nucleai, highlighted the significance of integrating high-plex spatial proteomics into clinical settings and how it enhances the accuracy of precision medicine. The findings of this trial underscore the value of spatial biomarkers in predicting treatment outcomes for patients.

Future Insights During SITC 2025

Bio-Techne's full portfolio related to spatial biology, including the newly introduced ProximityScope™ assay and the extended SPYRE™ portfolio, will be showcased at Booth #603 during the SITC 2025. Visual data from the SECOMBIT study will also be presented in Poster #528, representing a collaboration that seeks to redefine the landscape of cancer treatment through precision medicine.

About the Companies

Bio-Techne Corporation (NASDAQ: TECH) is renowned for providing innovative life sciences tools, bioactive reagents, and diagnostic products aimed at enhancing biological research and clinical diagnostics. In fiscal 2025, Bio-Techne achieved over $1.2 billion in net sales and employs approximately 3,100 individuals worldwide.

Nucleai stands at the forefront of AI-driven multimodal spatial biology, transforming tissue imaging into actionable insights to enable more effective drug development and diagnostics. Through its multimodal spatial operating system, Nucleai partners with pharmaceutical and academic institutions globally, offering critical innovations for next-generation precision medicine products.

For those interested in pioneering developments in immunotherapy and melanoma research, the presentations at SITC 2025 promise to be rich with transformative insights that will pave the way for more effective and personalized cancer treatments.